Diligence memo · auto-generated · as of July 2, 2026
Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Nuo Therapeutics, Inc. operates in Pharma, based in Houston.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nuo Therapeutics, Inc. has raised $46M in disclosed capital across 16 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $21M on 2012-02-08.
Most recent recorded round closed around 2025-07-30.
Valuation (modeled)modeled
Provath models Nuo Therapeutics, Inc. at approximately $3.6M (range $1.7M–$5.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.04× the median modeled value of Series B Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 11 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharma peers (310 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Juvena Therapeutics, Inc., Alessa Therapeutics, Inc., Amani Therapeutics, Inc., Shenandoah Therapeutics Inc., Atlas Oncology Holdings Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.